Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label, Multicenter Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients With Elevated Resting Heart Rate

Trial Profile

A Phase 3, Open-label, Multicenter Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients With Elevated Resting Heart Rate

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Tachycardia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 15 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 25 Sep 2018 Planned End Date changed from 6 Sep 2019 to 19 Feb 2020.
    • 25 Sep 2018 Planned primary completion date changed from 6 Sep 2019 to 19 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top